Clinical Trial Update: A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for anlotinib and AK105 injection in patients with gastrointestinal, urinary system, and neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Tumors
• Neuroendocrine Tumors
• Urinary System Tumors

Drugs mentioned

• AK105 Injection
• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors | Phase 2 | Status: UNKNOWN